Skip to main content

Table 1 Patient counts for each model by response

From: Leveraging TCGA gene expression data to build predictive models for cancer drug response

Model Responder Count Non-responder Count Total Count
Fluorouracil pan-cancera 34 24 58
Gemcitabine pan-cancerb 37 55 92
  1. aFluorouracil pan-cancer includes: colon adenocarcinoma, esophageal carcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma
  2. bGemcitabine pan-cancer includes: bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, head and neck squamous cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, sarcoma, skin cutaneous melanoma, testicular germ cell tumors, uterine corpus endometrial carcinoma